IntrinsicIntrinsic
← All summaries

CLOVER HEALTH INVESTMENTS, CORP. /DE

CLOV
Financials & Chart →

Business Summary

Clover Health Investments, Corp. operates in the healthcare industry, specifically within the Medicare Advantage (MA) market, which accounted for approximately $545 billion of annual spend in 2025 and is projected to grow to approximately $916 billion by 2030. The total Medicare market encompassed approximately 70 million people in 2025, with total expenditures expected to reach approximately $1.5 trillion by 2030. The company's strategy is to improve care for MA members, develop wide physician networks, and provide technology to empower physicians, primarily by deploying its proprietary software platform, Clover Assistant.

The company's core business model revolves around generating revenue from Medicare Advantage premiums through its Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans. These plans are designed to offer affordable, high-quality healthcare with low average out-of-pocket costs for primary care provider (PCP) and specialist co-pays in their respective markets. A significant feature of their MA product is its wide physician network, often offering the same cost-sharing for in-network and out-of-network primary care providers. The company's revenue is primarily driven by the number of members under its MA plans.

Clover Assistant, the company's proprietary software platform, supports clinical real-time decision-making by equipping clinicians with data and insights curated from over 100 sources. This platform enables physicians to detect, identify, and manage chronic diseases earlier. The more providers use Clover Assistant, the more it learns and refines its personalized data-driven recommendations, creating a closed feedback loop that continuously improves clinical rules and machine learning models. The company also operates a longitudinal home-based primary care program for its highest acuity members, Clover Home Care, which is powered by Clover Assistant.

In 2024, the company launched Counterpart Health, Inc., a subsidiary offering a Software-as-a-Service (SaaS) and Tech Enabled Services Solution to bring the Clover Assistant technology to external payors and providers serving the Medicare eligible population under the brand name "Counterpart Assistant." This external offering aims to extend the benefits of data-driven technology and personalized care to a wider audience, enabling enhanced patient outcomes and reduced healthcare costs. Counterpart Health is complementary to Clover Health and is intended to drive new potential growth and high-margin business opportunities with low startup costs, though it is not yet significant to the overall business or results of operations.

For the fiscal year ended December 31, 2025, Clover Health reported total revenues of $1,924,308 thousand , an increase from $1,371,131 thousand in 2024. Net medical claims incurred were $1,568,406 thousand , compared to $1,006,327 thousand in 2024. The company reported a net loss from continuing operations of $85,549 thousand for 2025, an increase from a net loss of $46,266 thousand in 2024. Basic and diluted loss per share from continuing operations was $0.17 in 2025, compared to $0.09 in 2024. Cash and cash equivalents stood at $78,301 thousand at December 31, 2025, down from $194,543 thousand at December 31, 2024. Total liabilities were $232,307 thousand at December 31, 2025, and total stockholders' equity was $308,704 thousand .

Comparing 2025 to 2024, total revenues increased by $553,177 thousand , or 40.3% . This was primarily driven by a 41% increase in premiums earned, net, to $1,891,732 thousand from $1,344,881 thousand , largely due to an approximate 33% increase in average members. Net medical claims incurred increased by $562,079 thousand , or 55.9% , to $1,568,406 thousand , primarily due to member growth and an increase in Part D cost sharing from the Inflation Reduction Act. Salaries and benefits decreased by $7,000 thousand , or 3% , to $225,475 thousand , while general and administrative expenses increased by $37,800 thousand , or 21% , to $214,270 thousand . The Insurance Benefits expense ratio (BER) was 90.9% in 2025, up from 81.2% in 2024. The Normalized Insurance Benefits expense ratio was 91.5% in 2025, compared to 84.2% in 2024.

During 2024, the company launched Counterpart Health, Inc. to extend Clover Assistant technology to external payors and providers. For the 2026 rating year, CMS decreased the Star rating of its PPO Medicare Advantage plans to 3.5 Stars and increased the rating of its HMO MA plan to 4.0 Stars . The company announced a 53% year-over-year growth of its MA membership during the most recent Annual Election Period, entering 2026 with over 153,000 members, with over 97% enrolled in PPO plans. The company's MA plans will be available in a total of 203 counties and five states beginning in 2026.

Business Outlook

The company expects to continue investing significant additional funds towards growing its business, specifically in improving Clover Assistant and its technology infrastructure, developing clinical care programs, increasing adoption of the Clover Assistant platform, including through Counterpart Health, expanding marketing and outreach efforts, expanding operations geographically, and developing future offerings. These investments are anticipated to be more expensive than currently projected, and there is no assurance that revenue will increase sufficiently to offset these expenses. The company's ability to maintain profitability or achieve positive cash flow in any given period is not guaranteed, and additional financing may be required, which could be dilutive to stockholders.

A major growth area for the company is the expansion of Clover Assistant to external partners through its subsidiary, Counterpart Health, Inc., under the brand name Counterpart Assistant. This Software-as-a-Service (SaaS) and tech-enabled services solution aims to bring the AI-powered care management platform to external payors and providers serving the Medicare eligible population. This offering is designed to extend the benefits of data-driven technology and personalized care to a wider audience, enabling enhanced patient outcomes and reduced healthcare costs across the nation. Counterpart Health is complementary to Clover Health and is expected to drive new potential growth and high-margin business opportunities with low startup costs. The company is continuing external commercialization efforts to increase total lives on Counterpart Health alongside Clover's growing Medicare Advantage Plan.

The company's future performance is heavily dependent on its ability to utilize Clover Assistant to drive down the medical care ratios for its members, aiming to achieve per member per month (PMPM) medical expense savings and generate more accurate risk adjustment data over time. If these decreases in cost of care are not realized, the business, financial condition, and results of operations will be adversely affected. The company also relies on its clinical care capabilities to improve the quality of care for members to ensure retention, as returning members tend to have lower Medical Care Ratios (MCRs) than new members.

The company plans to continue investing resources in improving and enhancing Clover Assistant, with the success of any enhancements dependent on timely completion and delivery, adequate quality testing, integration with existing technologies, adequate training and messaging to providers, and overall market acceptance. The company must also ensure its platform can scale to meet the evolving needs of users as it expands its business and provider user base.

Planned capital allocation includes continued investment in research and development for the Clover Assistant platform. The company's Board of Directors authorized the repurchase of up to $20.0 million in shares of Class A common stock over a two-year period on May 6, 2024. This repurchase program was exhausted in the first quarter of 2025, and the company may enter into a new repurchase program in the future. The company does not intend to pay any cash dividends in the foreseeable future, anticipating that all future earnings will be retained for business development and general corporate purposes.

Management has explicitly flagged several structural headwinds and execution risks to its growth plan. These include the potential for lower-than-expected adoption and use of Clover Assistant, which could slow or stall growth, or a decline in the number of lives under Clover management. The company also faces challenges in accurately estimating, pricing for, and managing medical expenses, which could lead to declining profitability. The Centers for Medicare & Medicaid Services' (CMS) risk adjustment payment system introduces unpredictability in revenue and profitability, with potential for material retroactive adjustments. The company's reliance on Medicare Advantage premiums means that changes or developments in Medicare generally, or in health insurance laws and regulations, could materially adversely affect the business.

Risk Factors

The company faces several material risks, including the inability to achieve or maintain profitability, as evidenced by net losses of $85.5 million , $46.3 million , and $210.1 million for the years ended December 31, 2025, 2024, and 2023, respectively, and an accumulated deficit of approximately $2.3 billion as of December 31, 2025. A significant risk is the dependence on maintaining and improving Clover Assistant and the successful expansion of Counterpart Assistant, as past results may not indicate future performance. Failure to effectively estimate, price for, and manage medical expenses, including those related to the ACA's 85% minimum medical loss ratio threshold, could decline profitability. CMS's risk adjustment payment system makes revenues and profitability difficult to predict and could result in material retroactive adjustments. The company is highly exposed to changes in Medicare Advantage premiums, which account for substantially all of its total revenues. Geographic concentration of members, with approximately 87% in New Jersey at December 31, 2025, exposes the company to disproportionately adverse effects from unfavorable changes in local benefit costs, reimbursement rates, competition, and economic conditions. Operational risks include the inability to grow provider networks or contract on competitive terms, and challenges in effectively managing growth, which could lead to unexpected expenses or weaknesses in infrastructure. Cybersecurity risks are significant, with potential for security breaches or cyber incidents to damage reputation, harm business, and result in substantial costs and liabilities, as exemplified by the 2024 ransomware attack on a vendor, UnitedHealth Group’s Change Healthcare. The company is also subject to ongoing investigations and litigation, including inquiries from the U.S. Department of Justice, which can be costly and time-consuming. Compliance with federal and state privacy and security regulations, such as HIPAA and the CCPA, is critical, and failure to comply could result in significant liability or reputational harm. International operations, particularly in Hong Kong and Canada, expose the company to uncertain political climates, potential disruptions in international trade, and increased data security and privacy risks. The dual class stock structure, with directors and executive officers holding 71.2% of the voting power at December 31, 2025, concentrates control and may limit the influence of other stockholders.

Management Priorities

Management's message to shareholders emphasizes a vision to empower every physician with technology to identify, manage, and treat chronic diseases earlier, leading to earlier diagnosis and treatment, earlier disease management, and more affordable and accessible care. The strategic priorities include improving care for Medicare Advantage members, developing wide physician networks, and providing technology to empower physicians through the proprietary software platform, Clover Assistant. Management highlighted the 53% year-over-year growth in MA membership during the most recent Annual Election Period, with over 153,000 members entering 2026, and over 97% enrolled in PPO plans. They also noted the increase in the HMO MA plan's Star Rating to 4.0 Stars for the 2026 rating year, despite a decrease in the PPO MA plans' rating to 3.5 Stars . Management explicitly stated that they do not intend to pay any cash dividends in the foreseeable future, anticipating that all future earnings will be retained for business development and general corporate purposes.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Our Opportunity
  2. [2] Item 1, Business — Our Opportunity
  3. [3] Item 1, Business — Our Opportunity
  4. [4] Item 1, Business — Our Opportunity
  5. [5] Item 7, MD&A — Key Performance Measures
  6. [6] Item 7, MD&A — Key Performance Measures
  7. [7] Item 7, MD&A — Key Performance Measures
  8. [8] Item 7, MD&A — Key Performance Measures
  9. [9] Item 7, MD&A — Results of Operations Comparison of the Years ended December 31, 2025 and 2024
  10. [10] Item 7, MD&A — Results of Operations Comparison of the Years ended December 31, 2025 and 2024
  11. [11] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  12. [12] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  13. [13] Item 8, Consolidated Balance Sheets
  14. [14] Item 8, Consolidated Balance Sheets
  15. [15] Item 8, Consolidated Balance Sheets
  16. [16] Item 8, Consolidated Balance Sheets
  17. [17] Item 7, MD&A — Results of Operations Comparison of the Years ended December 31, 2025 and 2024
  18. [18] Item 7, MD&A — Results of Operations Comparison of the Years ended December 31, 2025 and 2024
  19. [19] Item 7, MD&A — Premiums earned, net
  20. [20] Item 7, MD&A — Premiums earned, net
  21. [21] Item 7, MD&A — Premiums earned, net
  22. [22] Item 7, MD&A — Premiums earned, net
  23. [23] Item 7, MD&A — Net medical claims incurred
  24. [24] Item 7, MD&A — Net medical claims incurred
  25. [25] Item 7, MD&A — Net medical claims incurred
  26. [26] Item 7, MD&A — Salaries and benefits
  27. [27] Item 7, MD&A — Salaries and benefits
  28. [28] Item 7, MD&A — Salaries and benefits
  29. [29] Item 7, MD&A — General and administrative expenses
  30. [30] Item 7, MD&A — General and administrative expenses
  31. [31] Item 7, MD&A — General and administrative expenses
  32. [32] Item 7, MD&A — Key Performance Measures
  33. [33] Item 7, MD&A — Key Performance Measures
  34. [34] Item 7, MD&A — Key Performance Measures
  35. [35] Item 7, MD&A — Key Performance Measures
  36. [36] Item 7, MD&A — 2025 Highlights
  37. [37] Item 7, MD&A — 2025 Highlights
  38. [38] Item 7, MD&A — 2025 Highlights
  39. [39] Item 7, MD&A — 2025 Highlights
  40. [40] Item 7, MD&A — 2025 Highlights
  41. [41] Item 7, MD&A — 2025 Highlights
  42. [42] Item 7, MD&A — 2025 Highlights
  43. [43] Item 5, Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  44. [44] Item 1A, Risk Factors — We have incurred net losses in the past, and we may not be able to achieve or maintain profitability in the future.
  45. [45] Item 1A, Risk Factors — We have incurred net losses in the past, and we may not be able to achieve or maintain profitability in the future.
  46. [46] Item 1A, Risk Factors — We have incurred net losses in the past, and we may not be able to achieve or maintain profitability in the future.
  47. [47] Item 1A, Risk Factors — We have incurred net losses in the past, and we may not be able to achieve or maintain profitability in the future.
  48. [48] Item 1A, Risk Factors — If we fail to estimate, price for and manage medical expenses in an effective manner, the profitability of our business could decline, which could materially and adversely affect our results of operations, financial condition, and cash flows.
  49. [49] Item 1A, Risk Factors — Our members remain concentrated in certain geographic areas and populations, which exposes us to unfavorable changes in local benefit costs, reimbursement rates, competition, and economic conditions.
  50. [50] Item 1A, Risk Factors — The dual class structure of our common stock has the effect of concentrating voting control with certain stockholders, including our directors and executive officers and their respective affiliates, who held in the aggregate 71.2% of the voting power of our capital stock at December 31, 2025.
  51. [51] Item 7, MD&A — 2025 Highlights
  52. [52] Item 7, MD&A — 2025 Highlights
  53. [53] Item 7, MD&A — 2025 Highlights
  54. [54] Item 7, MD&A — 2025 Highlights
  55. [55] Item 7, MD&A — 2025 Highlights

Analysis on 5/20/2026